Abstract:It has been previously reported that human embryonic fibroblasts and mouse embryonic fibroblasts can be converted into neuronal cells using chemical agents, along with forced expression specific transcriptional factors. However, the materials required for reprogramming in these approaches presents major technical difficulties and safety concerns. The current study investigated whether a cocktail of small molecules can convert human lung fibroblast cells into neurons. The small molecules valproic acid, CHIR9902… Show more
“…Indeed, the correlation analysis showed that hepatic H19 mRNA levels were positively correlated with hepatic TGFB1 mRNA and ACTA2, suggesting that H19 mRNA levels could be used to monitor LF progression in BA patients. Similar to the findings in mouse CLI models, the current study showed that H19 levels were markedly increased in serum exosomes isolated from BA patients compared to those in controls. Given that exosomal and hepatic H19 levels are associated with LF in BA patients, serum exosomal H19 levels may be utilized as a useful marker for monitoring LF progression of BA patients.…”
Section: Discussionsupporting
confidence: 89%
“…H19 is highly expressed in fetal liver, but repressed significantly after birth. Intriguingly, it has been reported that H19 is up‐regulated in human liver diseases and CLI animal models, including CCl 4 ‐induced liver injury, bile duct ligation (BDL)‐induced cholestatic injury, and the multidrug resistance 2 knockout ( Mdr2 –/– ) mouse model, implicating its important role in disease progression of CLI. Our recent studies indicate that hepatic H19 level is correlated with severity of cholestatic injury in Mdr2 –/– mice .…”
Biliary atresia (BA) is a neonatal liver disease featuring cholestasis and severe liver fibrosis (LF). Despite advances in the development of surgical treatment, lacking an early diagnostic marker and intervention of LF invariably leads to death from end-stage liver disease in the early years of life. We previously reported that knockout of sphingosine 1-phosphate receptor 2 (S1PR2) protected mice from bile duct ligation (BDL)-induced cholangiocyte proliferation and LF. Our recent studies further showed that both hepatic and serum exosomal long noncoding RNA H19 (lncR-NAH19) levels are correlated with cholestatic injury in multidrug resistance 2 knockout (Mdr2−/−) mice. However, the role of lncRNAH19 in BA progression remains unclear. Here, we show that both hepatic and serum exosomal H19 levels are positively correlated with severity of fibrotic liver injuries in BA patients. H19 deficiency protects mice from BDL-induced cholangiocyte proliferation and LF by inhibiting bile-acid–induced expression and activation of S1PR2 and sphingosine kinase 2 (SphK2). Furthermore, H19 acts as a molecular sponge for members of the microRNA let-7 family, which results in up-regulation of high-mobility group AT-hook 2 (HMGA2), a known target of let-7 and enhancement of biliary proliferation. Conclusion: These results indicate that H19 plays a critical role in cholangiocyte proliferation and cholestatic liver injury in BA by regulating the S1PR2/SphK2 and let-7/HMGA2 axis. Serum exosomal H19 may represent a noninvasive diagnostic biomarker and potential therapeutic target for BA.
“…Indeed, the correlation analysis showed that hepatic H19 mRNA levels were positively correlated with hepatic TGFB1 mRNA and ACTA2, suggesting that H19 mRNA levels could be used to monitor LF progression in BA patients. Similar to the findings in mouse CLI models, the current study showed that H19 levels were markedly increased in serum exosomes isolated from BA patients compared to those in controls. Given that exosomal and hepatic H19 levels are associated with LF in BA patients, serum exosomal H19 levels may be utilized as a useful marker for monitoring LF progression of BA patients.…”
Section: Discussionsupporting
confidence: 89%
“…H19 is highly expressed in fetal liver, but repressed significantly after birth. Intriguingly, it has been reported that H19 is up‐regulated in human liver diseases and CLI animal models, including CCl 4 ‐induced liver injury, bile duct ligation (BDL)‐induced cholestatic injury, and the multidrug resistance 2 knockout ( Mdr2 –/– ) mouse model, implicating its important role in disease progression of CLI. Our recent studies indicate that hepatic H19 level is correlated with severity of cholestatic injury in Mdr2 –/– mice .…”
Biliary atresia (BA) is a neonatal liver disease featuring cholestasis and severe liver fibrosis (LF). Despite advances in the development of surgical treatment, lacking an early diagnostic marker and intervention of LF invariably leads to death from end-stage liver disease in the early years of life. We previously reported that knockout of sphingosine 1-phosphate receptor 2 (S1PR2) protected mice from bile duct ligation (BDL)-induced cholangiocyte proliferation and LF. Our recent studies further showed that both hepatic and serum exosomal long noncoding RNA H19 (lncR-NAH19) levels are correlated with cholestatic injury in multidrug resistance 2 knockout (Mdr2−/−) mice. However, the role of lncRNAH19 in BA progression remains unclear. Here, we show that both hepatic and serum exosomal H19 levels are positively correlated with severity of fibrotic liver injuries in BA patients. H19 deficiency protects mice from BDL-induced cholangiocyte proliferation and LF by inhibiting bile-acid–induced expression and activation of S1PR2 and sphingosine kinase 2 (SphK2). Furthermore, H19 acts as a molecular sponge for members of the microRNA let-7 family, which results in up-regulation of high-mobility group AT-hook 2 (HMGA2), a known target of let-7 and enhancement of biliary proliferation. Conclusion: These results indicate that H19 plays a critical role in cholangiocyte proliferation and cholestatic liver injury in BA by regulating the S1PR2/SphK2 and let-7/HMGA2 axis. Serum exosomal H19 may represent a noninvasive diagnostic biomarker and potential therapeutic target for BA.
“…LncRNA H19 (both hepatic and serum exosomal long noncoding RNA H19) is an imprinted and maternally expressed gene that is conserved between humans and mice and is involved in the regulation of cell proliferation and differentiation [95,96]. A previous study found that H19 is upregulated in CLI animal models and human liver diseases [92,97,98]. H19 plays an important role in the process of liver fibrosis, with inhibition and promotion mediated by different targets.…”
Section: Both Inhibition and Promotion Of Liver Fibrosis By Lncrnamentioning
confidence: 99%
“…As is a master profibrogenic cytokine, TGF-β controls liver physiology and pathology during the initial process of liver injury-inflammation-fibrosis [92,96,97]. TGF-β influences the different biological processes of liver fibrogenesis, including the circadian rhythm, epigenetics, reactive oxygen species generation, metabolism, senescence, EMT, and endothelial to mesenchymal transition [97]. To date, it has been found that lncRNAs cooperate with the TGF-β signalling pathway to regulate HSC activation and hepatic fibrosis.…”
Section: Signalling Pathways Involved In Liver Fibrosismentioning
Many studies have revealed that circulating long noncoding RNAs (lncRNAs) regulate gene and protein expression in the process of hepatic fibrosis. Liver fibrosis is a reversible wound healing response followed by excessive extracellular matrix accumulation. In the development of liver fibrosis, some lncRNAs regulate diverse cellular processes by acting as competing endogenous RNAs (ceRNAs) and binding proteins. Previous investigations demonstrated that overexpression of lncRNAs such as H19, maternally expressed gene 3 (MEG3), growth arrest-specific transcript 5 (GAS5), Gm5091, NR_002155.1, and HIF 1alpha-antisense RNA 1 (HIF1A-AS1) can inhibit the progression of liver fibrosis. Furthermore, the upregulation of several lncRNAs [e.g., nuclear paraspeckle assembly transcript 1 (NEAT1), hox transcript antisense RNA (Hotair), and liver-enriched fibrosis-associated lncRNA1 (lnc-LFAR1)] has been reported to promote liver fibrosis. This review will focus on the functions and mechanisms of lncRNAs, the lncRNA transcriptome profile of liver fibrosis, and the main lncRNAs involved in the signalling pathways that regulate hepatic fibrosis. This review provides insight into the screening of therapeutic and diagnostic markers of liver fibrosis.
“…At the same time, Pei's work revealed that human fibroblasts were able to transdifferentiate into neurons by a different chemical cocktail (VPA, CHIR99021, RepSox, Forskolin, SP600125, Gö6983, and Y-27632) [ 40 ]. It was also reported that human lung fibroblasts could be converted into neurons using a similar small molecule combination, including VPA, CHIR99021, DMH1, RepSox, Forskolin, Y-27632, and SP600125 [ 41 ].…”
Although innovative technologies for somatic cell reprogramming and transdifferentiation provide new strategies for the research of translational medicine, including disease modeling, drug screening, artificial organ development, and cell therapy, recipient safety remains a concern due to the use of exogenous transcription factors during induction. To resolve this problem, new induction approaches containing clinically applicable small molecules have been explored. Small molecule epigenetic modulators such as DNA methylation writer inhibitors, histone methylation writer inhibitors, histone acylation reader inhibitors, and histone acetylation eraser inhibitors could overcome epigenetic barriers during cell fate conversion. In the past few years, significant progress has been made in reprogramming and transdifferentiation of somatic cells with small molecule approaches. In the present review, we systematically discuss recent achievements of pure chemical reprogramming and transdifferentiation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.